2025 China Anti-Obesity Drugs Market Revenue Opportunities Report
Description
The 2025 China Anti-Obesity Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-obesity drugs market in China include Hansoh Pharma, Novo Nordisk, Eli Lilly, and Merck & Co. Hansoh Pharma, a China-based company, has partnered with Merck & Co. through a licensing deal granting Merck rights outside China to the oral GLP-1 agonist HS-10535, while Hansoh retains commercialization rights within China. Novo Nordisk dominates the global market with its strong product portfolio, including the FDA-approved injection Wegovy for chronic weight management; the company is expanding its presence in China amid increasing demand for obesity treatments. Eli Lilly is advancing novel obesity treatments like tirzepatide and retatrutide, including ongoing trials expected to deliver new options that could penetrate the Chinese market. Merck & Co., with its sizable development pipeline and licensing strategy, is also growing its footprint in China by working with Chinese biotechs like Hansoh, signaling serious investment in obesity drugs in this region.
In addition to these multinational firms, Chinese companies such as Sciwind Biosciences are innovating next-generation obesity drugs like ecnoglutide, which have shown promising trial results with significant weight loss and cardiovascular benefits. The Chinese market is becoming a hub for both generics mimicking global best sellers and original discoveries aimed at local and international markets. With the rapid growth projected for the anti-obesity drugs market in China and Asia, these companies are strategically positioned to capture substantial market share through innovative products and partnerships. The combination of domestic innovation and global pharmaceutical collaborations underlines the dynamic and competitive nature of China's role in the global anti-obesity drug landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Obesity Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the anti-obesity drugs market in China include Hansoh Pharma, Novo Nordisk, Eli Lilly, and Merck & Co. Hansoh Pharma, a China-based company, has partnered with Merck & Co. through a licensing deal granting Merck rights outside China to the oral GLP-1 agonist HS-10535, while Hansoh retains commercialization rights within China. Novo Nordisk dominates the global market with its strong product portfolio, including the FDA-approved injection Wegovy for chronic weight management; the company is expanding its presence in China amid increasing demand for obesity treatments. Eli Lilly is advancing novel obesity treatments like tirzepatide and retatrutide, including ongoing trials expected to deliver new options that could penetrate the Chinese market. Merck & Co., with its sizable development pipeline and licensing strategy, is also growing its footprint in China by working with Chinese biotechs like Hansoh, signaling serious investment in obesity drugs in this region.
In addition to these multinational firms, Chinese companies such as Sciwind Biosciences are innovating next-generation obesity drugs like ecnoglutide, which have shown promising trial results with significant weight loss and cardiovascular benefits. The Chinese market is becoming a hub for both generics mimicking global best sellers and original discoveries aimed at local and international markets. With the rapid growth projected for the anti-obesity drugs market in China and Asia, these companies are strategically positioned to capture substantial market share through innovative products and partnerships. The combination of domestic innovation and global pharmaceutical collaborations underlines the dynamic and competitive nature of China's role in the global anti-obesity drug landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
